Ukr.Biochem.J. 2019; Volume 91, Issue 6, Nov-Dec, pp. 79-85


The concentration of ceruloplasmin in blood of tumor-bearing rats after administration of a dirhenium(III) compound and cisplatin

O. I. Hrabovska1, K. L. Shamelashvili2, O. V. Shtemenko4, N. I. Shtemenko3,4

1Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine, Dnipro;
2SI “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro;
3Dnipro University of Technology, Ukraine;
4Ukrainian State University of Chemical Technology, Dnipro;

Received: 18 January 2019; Accepted: 18 October 2019

Contemporary investigations of mechanisms of resistance to platinides showed the key role of copper metabolism in cancer patients and proposed possible methods to attenuate the resistance by modulation of copper transporting mechanisms. In this vein, investigation of ceruloplasmin (Cp) levels – the main copper-containing protein in blood, in experiments with tumor-containing animals upon cytostatics administration is topical and has great importance. The concentration of Cp was measured in the serum of tumor-bearing rats with ordinary (T8) and resistant to cisplatin (T8*) Guerin’s carcinoma upon administration of cisplatin and quadruple bonding dirhenium(III) compound dichlorotetra-μ-isobutyratodirhenium(ІІІ) (I) in different medicamental forms. It was shown that development of tumor in T8 group led to increasing of concentration of Cp in 3.7 times and in T8* group – more than in 8 times in comparison to control, confirming the essential role of Cp in the formation of resistance phenomenon. Administration of cisplatin together with I led to effective inhibition of tumor in groups with T8 and T8*, indicating decreased resistance in the group T8*. Greater reduction of Cp levels was observed in the groups with T8* upon administration of the rhenium-plati­num antitumor system, than in groups with T8, that underlines the importance of further investigations of the dirhenium(III) compounds in the resistance to cytostatics cancer models. Some mechanisms concerning the regulation of copper homeostasis and properties of nano-composites are discussed.

Keywords: , , ,


  1. White KN, Conesa C, Sánchez L, Amini M, Farnaud S, Lorvoralak C, Evans RW. The transfer of iron between ceruloplasmin and transferrins. Biochim Biophys Acta. 2012 Mar;1820(3):411-6. PubMed, CrossRef
  2. Tisato F, Marzano C, Porchia M, Pellei M, Santini C. Copper in diseases and treatments, and copper-based anticancer strategies. Med Res Rev. 2010 Jul;30(4):708-49. PubMed, CrossRef
  3. Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev. 2009 Feb;35(1):32-46. PubMed, CrossRef
  4. Han IW, Jang JY, Kwon W, Park T, Kim Y, Lee KB, Kim SW. Ceruloplasmin as a prognostic marker in patients with bile duct cancer. Oncotarget. 2017 Apr 25;8(17):29028-29037. PubMed, PubMedCentral, CrossRef
  5. Arner E, Forrest AR, Ehrlund A, Mejhert N, Itoh M, Kawaji H, Lassmann T, Laurencikiene J, Rydén M, Arner P; FANTOM Consortium. Ceruloplasmin is a novel adipokine which is overexpressed in adipose tissue of obese subjects and in obesity-associated cancer cells. PLoS One. 2014 Mar 27;9(3):e80274. PubMed, PubMedCentral, CrossRef
  6. Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NMZ, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Kovacs J, Mills GB, Zhang W, Lopez-Berestein G, Bhattacharya PK, Sood AK. Long noncoding RNA ceruloplasmin promotes cancer growth by altering glycolysis. Cell Rep. 2015 Dec 22;13(11):2395-2402.  PubMed, PubMedCentral, CrossRef
  7. Fu S, Naing A, Fu C, Kuo MT, Kurzrock R. Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther. 2012 Jun;11(6):1221-5. PubMed, PubMedCentral, CrossRef
  8. Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT. Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther. 2012 Nov;11(11):2483-94. PubMed, PubMedCentral, CrossRef
  9. Chen HH, Kuo MT. Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61. PubMed, PubMedCentral
  10. Hrabovska OI, Kyrychenko SV, Shtemenko NI. Oxidative stress intensity in blood of rats under development of carcinoma Gerenium and putting cisplatin. Med Chem. 2014;16(2):42-46. (In Ukrainian).
  11. Grabovska O, Skoryk O, Shamelashvili K, Shtemenko О, Shtemenko N. Biochemical characteristics of blood of rats with resistant Guerin carcinoma at introduction of rhenium-platinum antitumor system. Bull Probl Biol Med. 2017;(1(135)):124-131. (In Ukrainian).
  12. Shtemenko AV, Shtemenko NI. Rhenium–platinum antitumor systems. Ukr Biochem J. 2017;89(2):5-30. CrossRef
  13. Shtemenko AV, Chifotides H2, Yegorova DE, Shtemenko NI, Dunbar KR. Synthesis and X-ray crystal structure of the dirhenium complex Re2(i-C3H7COO)4Cl2 and its interactions with the DNA purine nucleobases. J Inorg Biochem. 2015 Dec;153:114-120.  PubMed, CrossRef
  14. Li Z, Shtemenko NI, Yegorova DY, Babiy SO, Brown AJ, Yang T, Shtemenko AV, Dunbar KR. Liposomes loaded with a dirhenium compound and cisplatin: preparation, properties and improved in vivo anticancer activity. J Liposome Res. 2015 Mar;25(1):78-87. PubMed, CrossRef
  15. Casagrande N, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer. Clin Cancer Res. 2014 Nov 1;20(21):5496-506. PubMed, CrossRef
  16. Catanzaro D, Nicolosi S, Cocetta V, Salvalaio M, Pagetta A, Ragazzi E, Montopoli M, Pasut G. Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells. Oncotarget. 2018 Mar 30;9(24):16847-16860.  PubMed, PubMedCentral, CrossRef
  17. Shamelashvili KL, Shtemenko NI, Leus LV, Babiy SO, Shtemenko OV. Changes in oxidative stress intensity in blood of tumor-bearing rats following different modes of administration of rhenium-platinum system. Ukr Biochem J. 2016 Jul-Aug;88(4):29-39. PubMed, CrossRef
  18. Shtemenko N, Collery P, Shtemenko A. Dichlorotetra-mu-Isobutyratodirhenium(III): enhancement of cisplatin action and RBC-stabilizing properties. Anticancer Res. 2007 Jul-Aug;27(4B):2487-92. PubMed

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.